Balyasny Asset Management LLC raised its stake in Thermo Fisher Scientific Inc (NYSE:TMO) by 570.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 68,286 shares of the medical research company’s stock after purchasing an additional 58,105 shares during the quarter. Balyasny Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $11,914,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in TMO. BlackRock Inc. raised its position in Thermo Fisher Scientific by 2,692.1% in the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock valued at $3,531,095,000 after purchasing an additional 22,165,530 shares during the period. Veritas Asset Management LLP raised its position in Thermo Fisher Scientific by 112.4% in the second quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock valued at $424,095,000 after purchasing an additional 1,286,259 shares during the period. Harbour Capital Advisors LLC raised its position in Thermo Fisher Scientific by 18,197.5% in the second quarter. Harbour Capital Advisors LLC now owns 1,201,051 shares of the medical research company’s stock valued at $6,884,000 after purchasing an additional 1,194,487 shares during the period. Vanguard Group Inc. raised its position in Thermo Fisher Scientific by 2.7% in the first quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock valued at $3,989,193,000 after purchasing an additional 695,079 shares during the period. Finally, Renaissance Technologies LLC raised its position in Thermo Fisher Scientific by 68.8% in the first quarter. Renaissance Technologies LLC now owns 1,373,044 shares of the medical research company’s stock valued at $210,900,000 after purchasing an additional 559,400 shares during the period. 83.61% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.24 by $0.07. The firm had revenue of $5.12 billion during the quarter, compared to analyst estimates of $5.03 billion. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The business’s revenue was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.03 EPS.

WARNING: This news story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://theolympiareport.com/2017/11/02/balyasny-asset-management-llc-grows-holdings-in-thermo-fisher-scientific-inc-tmo.html.

In other Thermo Fisher Scientific news, VP Peter E. Hornstra sold 3,894 shares of the business’s stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $185.18, for a total transaction of $721,090.92. Following the completion of the transaction, the vice president now owns 19,751 shares of the company’s stock, valued at approximately $3,657,490.18. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Seth H. Hoogasian sold 4,140 shares of the business’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $177.80, for a total transaction of $736,092.00. Following the transaction, the vice president now directly owns 25,518 shares of the company’s stock, valued at approximately $4,537,100.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,738 shares of company stock valued at $4,021,512. Company insiders own 0.49% of the company’s stock.

Several research analysts have commented on the company. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $215.00 price objective on the stock in a research report on Tuesday. Leerink Swann reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research report on Monday. Deutsche Bank AG set a $226.00 target price on Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Thursday, October 26th. Jefferies Group LLC reaffirmed a “hold” rating and set a $195.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, September 28th. Finally, Goldman Sachs Group, Inc. (The) assumed coverage on Thermo Fisher Scientific in a research report on Tuesday, September 26th. They set a “buy” rating and a $225.00 target price on the stock. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $205.71.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.